Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. (Q54222903)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

chronic myeloid leukemia

0 references

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jacob Vine

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Sara Bar Cohen

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Rosa Ruchlemer

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Neta Goldschmidt

4

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Moshe Levin

5

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Diana Libster

6

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Alexander Gural

7

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Moshe E Gatt

8

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

David Lavie

9

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Dina Ben-Yehuda

10

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Deborah Rund

11

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

publication date

19 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

55

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

11

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

2525-2531

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Drug transporters and imatinib treatment: implications for clinical practice

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

A "silent" polymorphism in the MDR1 gene changes substrate specificity

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Implications of genetic polymorphisms in drug transporters for pharmacotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Response definitions and European Leukemianet Management recommendations

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.893307

21 January 2018

Identifiers

10.3109/10428194.2014.893307

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/24524306

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54222903&oldid=1584550212"